Health
Freiburg immunologists decipher anti-cancer drug’s mode of operation – News-Medical.net
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University…
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients to investigate how CD20 organizes the nanostructures on the B cell membrane. If the protein is missing or Rituximab binds to it, the organization of the B cell surface…
-
Business16 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Business20 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business19 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Business9 hours agoBell Potter names more of the best ASX 200 stocks to buy in April